SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-044841
Filing Date
2024-11-12
Accepted
2024-11-12 17:16:28
Documents
80
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1106870
2 ex10-10.htm EX-10.10 329609
3 ex10-11.htm EX-10.11 22916
4 ex31-1.htm EX-31.1 12544
5 ex31-2.htm EX-31.2 12591
6 ex32-1.htm EX-32.1 6985
7 ex32-2.htm EX-32.2 6976
8 form10-q_001.jpg GRAPHIC 2383
  Complete submission text file 0001493152-24-044841.txt   6724857

Data Files

Seq Description Document Type Size
9 XBRL SCHEMA FILE erna-20240930.xsd EX-101.SCH 56656
10 XBRL CALCULATION FILE erna-20240930_cal.xml EX-101.CAL 70835
11 XBRL DEFINITION FILE erna-20240930_def.xml EX-101.DEF 249476
12 XBRL LABEL FILE erna-20240930_lab.xml EX-101.LAB 468865
13 XBRL PRESENTATION FILE erna-20240930_pre.xml EX-101.PRE 386953
83 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 777880
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

IRS No.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-11460 | Film No.: 241449872
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)